ALKS - Alkermes plc
| Previous Close | 46.15 |
| Open | 46.37 |
| Bid | 45.24 x 100 |
| Ask | 46.65 x 400 |
| Day's Range | 45.40 - 46.65 |
| 52 Week Range | 41.15 - 71.22 |
| Volume | 1,421,693 |
| Avg. Volume | 1,299,550 |
| Market Cap | 7.133B |
| Beta | 2.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.03 |
| Earnings Date | Apr 26, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.45 |
- CNBC Videos•6 days ago
Cramer's lightning round: Take a long-term view on Spotif...
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a newly public streaming play.
- Motley Fool•3 hours ago
Johnson & Johnson's First-Quarter 2018 Earnings Review
We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.
- PR Newswire•3 days ago
Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results
DUBLIN , April 19, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Apr. 26, 2018 , to discuss the company's ...
- Zacks•4 days ago
Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics
The biotech space was a witness to a series of events. while share price of several stocks moved up, a few fell substantially.
- ACCESSWIRE•4 days ago
Wired News – FDA Accepts NDA Review for Alkermes’ ALKS 5461 for Treatment of Major Depressive Disorder
LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on Alkermes PLC (NASDAQ: ALKS). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALKS as the Company's latest news hit the wire. On April 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies.
- Zacks•5 days ago
Alkermes Rallies as FDA Accepts NDA for Depression Drug
Shares of Alkermes (ALKS) rose when the FDA accepted for review the new drug application for its depression candidate ALKS 5461 two weeks after it had issued a Refusal to File letter.
- CNBC•6 days ago
Cramer's lightning round: Take a long-term view on Spotify
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a newly public streaming play.
- TheStreet.com•6 days ago
Alkermes Wins Quick Reversal From FDA on Antidepressant Drug
Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.
- MarketWatch•6 days ago
Alkermes's stock soars after FDA accepts NDA review, 2 weeks after refusing
Shares of Alkermes PLC soared 21% in premarket trade Monday, after the biopharmaceutical company said the Food and Drug Administration accepted for review the company's new drug application (NDA) for its ...
- PR Newswire•6 days ago
Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
DUBLIN, April 16, 2018 /PRNewswire/ -- Alkermes plc (ALKS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALKS 5461, a novel, once-daily, oral investigational medicine for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressant therapies. FDA's target action date for the ALKS 5461 NDA is Jan. 31, 2019.
Markit•9 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Motley Fool•11 days ago
Alkermes Has Some Decisions to Make
Following a recent setback, management has a tougher road ahead.
- GlobeNewswire•12 days ago
Consolidated Research: 2018 Summary Expectations for Alkermes plc, Net 1 UEPS Technologies, CoreCivic, Inc., Videocon d2h, Shinhan Financial Group, and Himax Technologies — Fundamental Analysis, Key Performance Indications
NEW YORK, April 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Markit•12 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Motley Fool•15 days ago
Will Shire Be Bought Out?
Takeda may make an offer to buy Shire, but it might prove costly. Also, the FDA slaps Alkermes with a dreaded Refusal to File letter.
- Zacks•17 days ago
FDA Refuses Alkermes Depression Drug Review: 4 Stocks in Focus
The FDA's refusal to review Alkermes' depression candidate AKLS 5461 has brought depression disease market in focus. Here we take a look at a few companies developing products for this market.
Markit•17 days agoSee what the IHS Markit Score report has to say about Alkermes PLC.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Motley Fool•18 days ago
Alkermes' Bad News Could Be Good News for Johnson & Johnson
A stumble at Alkermes could mean one less competitor for a new drug making its way through J&J's pipeline.
- Zacks•18 days ago
Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion
The biotech sector grabbed headlines last week as Edge Therapeutics crashed on news of discontinuation of its phase III study while Amgen's Blincyto got FDA's nod for label expansion.
- Zacks•19 days ago
Alkermes Sinks as FDA Refuses Depression Drug Review
Alkermes (ALKS) shares declined by more than 21% as it received a Refusal to File letter from the FDA for its pipeline candidate, ALKS 5461, which was developed for major depressive disorder (MDD).
- Business Wire•19 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Alkermes plc
Levi & Korsinsky announces it has commenced an investigation of Alkermes plc concerning possible violations of federal securities laws.
- MarketWatch•19 days ago
Alkermes execs say they’re flummoxed by embarrassing FDA drug refusal; stock plunges
The regulator said it wouldn’t even review the company’s depression drug application, saying there wasn’t enough evidence that it worked.
